Skip to main content
. 2023 Jan 19;24:18. doi: 10.1186/s12882-022-03054-5

Fig. 2.

Fig. 2

RAASi change following an HK episode in (a) the US and (b) Japan. ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, ARNi angiotensin receptor-neprilysin inhibitor, HK hyperkalemia, MRA mineralocorticoid receptor antagonist, RAASi renin-angiotensin-aldosterone system inhibitor